MARKET

NAVB

NAVB

Navidea Biopharm
OTCPK
0.067
-0.002
-2.89%
Closed 15:31 12/06 EST
OPEN
0.066
PREV CLOSE
0.069
HIGH
0.072
LOW
0.066
VOLUME
74.95K
TURNOVER
5.12K
52 WEEK HIGH
0.350
52 WEEK LOW
0.025
MARKET CAP
6.72M
P/E (TTM)
-1.2267
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NAVB last week (1127-1201)?
Weekly Report · 2d ago
Navidea settles litigation with Capital Royalty, stock rallies 30%
Navidea biopharmaceuticals settles litigation with capital royalty partners. The companies have been in litigation since 2016. Shares of navidea were up 30% in midday trading friday following the news. The company says the settlement resolves a legal judgment against the company.
Seeking Alpha · 5d ago
Weekly Report: what happened at NAVB last week (1120-1124)?
Weekly Report · 11/27 11:23
Weekly Report: what happened at NAVB last week (1113-1117)?
Weekly Report · 11/20 11:20
Weekly Report: what happened at NAVB last week (1106-1110)?
Weekly Report · 11/13 11:13
Weekly Report: what happened at NAVB last week (1030-1103)?
Weekly Report · 11/06 11:18
Weekly Report: what happened at NAVB last week (1023-1027)?
Weekly Report · 10/30 11:37
Weekly Report: what happened at NAVB last week (1016-1020)?
Weekly Report · 10/23 11:25
More
About NAVB
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Webull offers Navidea Biopharmaceuticals Inc stock information, including OTCPK: NAVB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAVB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NAVB stock methods without spending real money on the virtual paper trading platform.